Late G-CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled trial.

Abstract	Granulocyte colony-stimulating factor (G-CSF) is widely used to accelerate neutrophil recovery after allogeneic BMT or PBSC transplantation. The optimal time to start G-CSF treatment is not known. Forty-two patients undergoing allogeneic BMT or PBSC transplantation for hematological malignancies received G-CSF either on day 6 or on day 9 post transplant. The time to hematological recovery was monitored and the two groups were compared with respect to peritransplant morbidity and mortality. Recovery of the neutrophil counts to >0.1 x 10(9)/l, > 0.5 x 10(9)/l and >1.0 x 10(9)/l were not significantly different in either group. There was no difference in recovery of red blood cell and platelet counts and no difference between the two groups with respect to the number of febrile days or number of days on antibiotic treatment. Documented bacterial, viral or fungal infections did not occur more often when G-CSF treatment was started on day 9. Delaying treatment with G-CSF resulted in a significant reduction in the length of treatment from 13 to 10 days (23.1% reduction). Reducing the length of the treatment by 3 days lowered the costs by 395.40 Euro per patient. Delaying G-CSF treatment and starting on day 9 after BMT or PBSC transplantation is safe and results in a clear economic benefit.
Authors	B Himmelmann, A Himmelmann, K Furrer, J Halter, U Schanz
Journal	Bone marrow transplantation (Bone Marrow Transplant) Vol. 30 Issue 8 Pg. 491-6 (Oct 2002) ISSN: 0268-3369 [Print] England
PMID	12379887 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References	Granulocyte Colony-Stimulating Factor
Topics	Adolescent Adult Blood Cell Count Bone Marrow Transplantation (adverse effects, methods, mortality) Female Graft Survival (drug effects) Granulocyte Colony-Stimulating Factor (administration & dosage, economics) Hematologic Neoplasms (complications, mortality, therapy) Humans Kinetics Male Middle Aged Peripheral Blood Stem Cell Transplantation (adverse effects, methods, mortality) Prospective Studies Time Factors Transplantation, Homologous Transplantation, Isogeneic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!